Vernalis Therapeutics Inc. today announced that its parent company, Vernalis plc (LSE:VER) has acquired U.S. rights to MOXATAG® (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (Pragma). MOXATAG® is the first and only approved once-daily formulation of the widely-used antibiotic amoxicillin.